Literature DB >> 20571540

IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques.

Matthew P Morrow1, Jian Yan, Panyupa Pankhong, Devon J Shedlock, Mark G Lewis, Kendra Talbott, Roberta Toporovski, Amir S Khan, Niranjan Y Sardesai, David B Weiner.   

Abstract

Type III/lambda interferons (IFNs) were discovered less than a decade ago and are still in the process of being characterized. Although previous studies have focused on the function of IFN-lambda 3 (also known as interleukin (IL)-28B) in a small animal model, it is unknown whether these functions would translate to a larger, more relevant model. Thus in the present study, we have used DNA vaccination as a method of studying the influence of IFN-lambda 3 on adaptive immune responses in rhesus macaques. Results of our study show for the first time that IFN-lambda 3 has significant influence on antigen-specific CD8(+) T-cell function, especially in regards to cytotoxicity. Peripheral CD8(+) T cells from animals that were administered IFN-lambda 3 showed substantially increased cytotoxic responses as gauged by CD107a and granzyme B coexpression as well as perforin release. Moreover, CD8(+) T cells isolated from the mesenteric lymph nodes (MLN) of animals receiving IFN-lambda 3 loaded significant amounts of granzyme B upon extended antigenic stimulation and induced significantly more granzyme B-mediated cell death of peptide pulsed targets. These data suggest that IFN-lambda 3 is a potent effector of the immune system with special emphasis on CD8(+) T-cell killing functions which warrants further study as a possible immunoadjuvant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571540      PMCID: PMC2956930          DOI: 10.1038/mt.2010.118

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  33 in total

1.  The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding.

Authors:  Jordan H Chill; Sabine R Quadt; Rina Levy; Gideon Schreiber; Jacob Anglister
Journal:  Structure       Date:  2003-07       Impact factor: 5.006

Review 2.  The IFN gamma receptor: a paradigm for cytokine receptor signaling.

Authors:  E A Bach; M Aguet; R D Schreiber
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

3.  Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999).

Authors:  J S Yang; J J Kim; D Hwang; A Y Choo; K Dang; H Maguire; S Kudchodkar; M P Ramanathan; D B Weiner
Journal:  J Infect Dis       Date:  2001-08-29       Impact factor: 5.226

4.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

5.  SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques.

Authors:  Jean D Boyer; Tara M Robinson; Michele A Kutzler; R Parkinson; Sandra A Calarota; Maninder K Sidhu; Karuppiah Muthumani; Mark Lewis; George Pavlakis; Barbara Felber; David Weiner
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

6.  IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge.

Authors:  J I Sin; J J Kim; R L Arnold; K E Shroff; D McCallus; C Pachuk; S P McElhiney; M W Wolf; S J Pompa-de Bruin; T J Higgins; R B Ciccarelli; D B Weiner
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

7.  Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype.

Authors:  J J Kim; H C Maguire; L K Nottingham; L D Morrison; A Tsai; J I Sin; A A Chalian; D B Weiner
Journal:  J Interferon Cytokine Res       Date:  1998-07       Impact factor: 2.607

8.  Characterization of virus-responsive plasmacytoid dendritic cells in the rhesus macaque.

Authors:  Eugene Chung; Sheela B Amrute; Kristina Abel; Gunjan Gupta; Yichuan Wang; Christopher J Miller; Patricia Fitzgerald-Bocarsly
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

9.  Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group.

Authors:  T Schneider; H U Jahn; W Schmidt; E O Riecken; M Zeitz; R Ullrich
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

10.  IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity.

Authors:  Stephen G Maher; Faruk Sheikh; Anthony J Scarzello; Ana L Romero-Weaver; Darren P Baker; Raymond P Donnelly; Ana M Gamero
Journal:  Cancer Biol Ther       Date:  2008-04-24       Impact factor: 4.742

View more
  29 in total

1.  Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques.

Authors:  Matthew P Morrow; Jian Yan; Panyupa Pankhong; Bernadette Ferraro; Mark G Lewis; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Clin Vaccine Immunol       Date:  2010-08-04

Review 2.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

3.  Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Authors:  Kar Muthumani; Seleeke Flingai; Megan Wise; Colleen Tingey; Kenneth E Ugen; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2013-09-17       Impact factor: 3.452

Review 4.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

Review 5.  Clinical applications of DNA vaccines: current progress.

Authors:  Bernadette Ferraro; Matthew P Morrow; Natalie A Hutnick; Thomas H Shin; Colleen E Lucke; David B Weiner
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

6.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.

Authors:  Mark L Bagarazzi; Jian Yan; Matthew P Morrow; David B Weiner; Niranjan Y Sardesai; Xuefei Shen; R Lamar Parker; Jessica C Lee; Mary Giffear; Panyupa Pankhong; Amir S Khan; Kate E Broderick; Christine Knott; Feng Lin; Jean D Boyer; Ruxandra Draghia-Akli; C Jo White; J Joseph Kim
Journal:  Sci Transl Med       Date:  2012-10-10       Impact factor: 17.956

7.  HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells.

Authors:  Karuppiah Muthumani; Devon J Shedlock; Daniel K Choo; Paolo Fagone; Omkar U Kawalekar; Jonathan Goodman; Chaoran B Bian; Aarti A Ramanathan; Parikh Atman; Pablo Tebas; Michael A Chattergoon; Andrew Y Choo; David B Weiner
Journal:  J Immunol       Date:  2011-08-19       Impact factor: 5.422

8.  Induction of robust cellular immunity against HPV6 and HPV11 in mice by DNA vaccine encoding for E6/E7 antigen.

Authors:  Thomas H Shin; Panyupa Pankhong; Jian Yan; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2012-02-16       Impact factor: 3.452

Review 9.  Interferon-λs: special immunomodulatory agents and potential therapeutic targets.

Authors:  Ya-wen Zheng; Hui Li; Jin-pu Yu; Hua Zhao; Shizhen Emily Wang; Xiu-bao Ren
Journal:  J Innate Immun       Date:  2012-11-30       Impact factor: 7.349

10.  Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.

Authors:  Ryann C Guayasamin; Tracy D Reynolds; Xin Wei; Mai Fujiwara; Michael D Robek
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.